HPV Infections Vaccine Pipeline Analyzed by PNS Pharma in Its New Research Report Published at MarketPublishers.com

New research report “Human Papillomavirus Infections Vaccine Pipeline Analysis” drawn up by PNS Pharma is available at MarketPublishers.com.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
TD The Market Publishers Ltd

http://marketpublishers.com/

London, UK (PRWEB) June 17, 2014

Human papillomaviruses represent a group of over 150 viruses which are related to each other, with certain types of viruses being able to cause warts (papillomas). There exist only two human papillomavirus vaccines which are currently marketed worldwide. Both these vaccines are prepared with the use of the recombinant technology, which is taken from purified L1 structural proteins that self assemble to form HPV type-specific empty shells or virus-like particles (VLPs).

Spain, Australia, Germany, the UK, Canada, the US, Italy, Japan and France are among the top geographical markets for human papillomavirus infections vaccines. Australia and Canada are forecast to witness strong growth in the next 6-8 years, driven mainly by the launch of Merck’s V503 vaccine along with the inclusion of the male population in routine human papillomavirus vaccine recommendations. Moreover, Merck’s V503 vaccine has the potential to generate substantial revenues in the future. The sales of this vaccine in the US alone are anticipated to climb to almost USD 1.5 billion by 2022.

New research report “Human Papillomavirus Infections Vaccine Pipeline Analysis” drawn up by PNS Pharma is available at MarketPublishers.com

Report Details:

Title: Human Papillomavirus Infections Vaccine Pipeline Analysis
Published: June, 2014
Pages: 197
Price: US$ 1,800.00
http://marketpublishers.com/report/pharmaceuticals/vaccines/human-papillomavirus-infections-vaccine-pipeline-analysis.html

The research report presents a close look at the world market for drugs used to treat human papillomavirus infections. It provides a granular pipeline analysis, contains a detailed clinical trial assessment by country and phase, and also thoroughly discusses the most important industry related issues. The study gives access to a complete set of top-level data on the existing marketed drugs for treating human papillomavirus infections, uncovers important patent information, and overviews the suspended and discounted drugs. The report delves deep into the competitive environment and also provides detailed profiles of the key companies operating in the industry.

Companies profiled encompass: Advanced Viral Research, Valeant Pharmaceuticals, Biogen Idec, Inviragen, BioSphings, MedImmune, EyeGene, Merck & Co, Helix BioPharma and Inviragen.

Report Scope:

  •     Comprehensive overview of the world human papillomavirus infection drug market.
  •     Profound insights into the clinical pipeline.
  •     All-round assessment of human papillomavirus infections drug clinical trials by country and by phase.
  •     Summary of the marketed, reported and discounted drugs for treating human papillomavirus infection.
  •     Extensive analysis of the competitive landscape.
  •     Profiles of the dominant market participants.

More new research reports by the publisher can be found at PNS Pharma page.